公开(公告)号：US20250027228A1

公开(公告)日：2025-01-23

申请号：US18435324

申请日：2024-02-07

Applicant: Massachusetts Institute of Technology

Inventor： Dehua Zhao ,  Christopher A. Voigt ,  Michael Joseph Smanski

IPC: C40B50/06 ,  C12N15/10 ,  C12N15/66 ,  C40B40/06 ,  C40B40/08 ,  G16B20/00 ,  G16B20/20 ,  G16B20/30 ,  G16B35/00 ,  G16B35/10 ,  G16B35/20 ,  G16B40/00 ,  G16B50/00 ,  G16B50/30 ,  G16C20/60

Abstract: The invention relates to methods and products for generating diverse libraries of genetic material. The products include libraries and constructed nucleic acids as well as kits and databases and systems thereof.

公开(公告)号：US12152236B2

公开(公告)日：2024-11-26

申请号：US18050382

申请日：2022-10-27

Applicant: University of Washington

Inventor： Jay Shendure ,  Joseph Hiatt ,  Rupali Patwardhan ,  Emily Turner

IPC: C12P19/34 ,  C12N15/10 ,  C12N15/66 ,  C12Q1/6806 ,  C12Q1/6869 ,  C12Q1/6874 ,  C40B40/06 ,  C40B50/06

Abstract: The present disclosure relates to a method for preparing a DNA sequencing library that brings more distal fragmentation breakpoints into close proximity to the non-degenerate sequence tag. In an embodiment, the method comprises circularizing a target fragment library with a plurality of adaptor molecules to produce a population of first circularized double-stranded DNA molecules, wherein the plurality of adaptor molecules comprises a first defined sequence P1 comprising a first restriction enzyme recognition site R1, a degenerate sequence tag, and a second defined sequence P2 comprising a second restriction enzyme recognition site R2, such that at least one of the first circularized double-stranded DNA molecule comprises a non-degenerate sequence tag and a member of the target fragment library. The method is useful because some sequencing platforms perform optimally with template molecules that are relatively short, for example, less than about 500 base pairs in length.

公开(公告)号：US12123033B2

公开(公告)日：2024-10-22

申请号：US17079097

申请日：2020-10-23

Applicant: INTEGRATED DNA TECHNOLOGIES, INC.

Inventor： Jessica Woodley ,  Bernice Thommandru ,  Joseph Dobosy ,  Mark Behlke ,  Adam Clore ,  Garrett Rettig ,  Beimeng Sun

IPC: C12N15/66 ,  C12N9/22 ,  C12N15/113

CPC classification number: C12N9/22 ,  C12N15/113 ,  C12N15/66 ,  C12N2310/122 ,  C12N2310/20 ,  C12N2310/321 ,  C12N2310/531 ,  C12N2800/80

Abstract: Described herein are compositions and methods for improving homology directed repair (HDR) efficiency and reducing homology-independent integration following introduction of double strand breaks with engineered nucleases. Additionally, modifications to double stranded DNA donors to improve the donor potency and efficiency of homology directed repair following introduction of double stranded breaks with programmable nucleases.

公开(公告)号：US12116609B2

公开(公告)日：2024-10-15

申请号：US17159850

申请日：2021-01-27

Applicant: Wisconsin Alumni Research Foundation

Inventor： Brian Frederick Pfleger ,  Jacqueline Marie Rand ,  Christopher Robert Mehrer ,  Matthew Ryan Incha

IPC: C12P7/04 ,  C12N9/10 ,  C12N9/18 ,  C12N15/52 ,  C12N15/62 ,  C12N15/63 ,  C12N15/64 ,  C12N15/66 ,  C12N15/69 ,  C12P7/16 ,  C12P7/26

CPC classification number: C12P7/16 ,  C12N9/1029 ,  C12N9/18 ,  C12N15/52 ,  C12N15/62 ,  C12N15/63 ,  C12N15/64 ,  C12N15/66 ,  C12N15/69 ,  C12P7/26 ,  C12Y203/01009 ,  C12Y208/03 ,  C12Y301/01

Abstract: Described is a recombinant expression vector that enables a cell transformed to contain and express the vector to use levulinic acid as a carbon source, thereby converting levulnic acid into 2-butanne. Also described are genetically modified cells transformed to contain and express the vector and methods of using the cells to produce 2-butanone from a medium containing levulinic acid.

公开(公告)号：US20240309064A1

公开(公告)日：2024-09-19

申请号：US18637124

申请日：2024-04-16

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Shunhai Wang ,  Ning Li ,  Hunter Chen ,  Amardeep Singh Bhupender Bhalla ,  Shawn M. Lawrence ,  Amy S. Johnson ,  Meghan Casey ,  Jaimie Grapel

IPC: C07K14/71 ,  A61K38/18 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/28 ,  C12N5/00 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/02 ,  G01N30/80

CPC classification number: C07K14/71 ,  A61K38/1866 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/283 ,  C12N5/0018 ,  C12N5/0031 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/80 ,  C07K2317/622 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2800/10 ,  G01N2030/027

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

公开(公告)号：US20240294606A1

公开(公告)日：2024-09-05

申请号：US18638362

申请日：2024-04-17

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Shunhai Wang ,  Ning Li ,  Hunter Chen ,  Amardeep Singh Bhupender Bhalla ,  Shawn M. Lawrence ,  Amy Johnson ,  Meghan Casey ,  Jaimie Grapel

IPC: C07K14/71 ,  A61K38/18 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/28 ,  C12N5/00 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/02 ,  G01N30/80

CPC classification number: C07K14/71 ,  A61K38/1866 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/283 ,  C12N5/0018 ,  C12N5/0031 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/80 ,  C07K2317/622 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2800/10 ,  G01N2030/027

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

公开(公告)号：US12054533B2

公开(公告)日：2024-08-06

申请号：US17858629

申请日：2022-07-06

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Andrew Tustian ,  Ankit Vartak ,  Thomas Daly ,  Erica Pyles ,  Nisha Palackal ,  Shunhai Wang ,  Ning Li

IPC: C07K1/36 ,  A61K38/18 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K14/71 ,  C07K16/22 ,  C07K16/28 ,  C12N5/00 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/80 ,  G01N30/02

CPC classification number: C07K14/71 ,  A61K38/1866 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/283 ,  C12N5/0018 ,  C12N5/0031 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/80 ,  C07K2317/622 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2800/10 ,  G01N2030/027

Abstract: The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.

公开(公告)号：US20240247276A1

公开(公告)日：2024-07-25

申请号：US18442726

申请日：2024-02-15

Applicant: Donald Danforth Plant Science Center ,  The Curators of the University of Missouri

Inventor： Blake Meyers ,  Rebecca Bart ,  Kira Veley ,  Ihuoma Okwuonu ,  Ryan DelPercio

IPC: C12N15/66 ,  C12N15/115

CPC classification number: C12N15/66 ,  C12N15/115 ,  C12N2310/20 ,  C12Q2521/301

Abstract: Compositions and methods for efficiently generating and identifying accurate homologous recombination events are disclosed.

公开(公告)号：US12043651B2

公开(公告)日：2024-07-23

申请号：US16861496

申请日：2020-04-29

Applicant: Hoffmann-La Roche Inc.

Inventor： Guy Georges ,  Josef Platzer

IPC: C07K14/705 ,  C07K16/46 ,  C12N15/66

CPC classification number: C07K14/705 ,  C12N15/66 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2319/73 ,  C07K2319/80

Abstract: Herein is reported a multimeric fusion polypeptide comprising five monomeric fusion polypeptides each comprising at least a Fab fragment and a COMP-domain of SEQ ID NO: 01 or a functional fragment thereof.

公开(公告)号：US20240209369A1

公开(公告)日：2024-06-27

申请号：US18594132

申请日：2024-03-04

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： Mark Keating ,  James D. McIninch ,  Elane Fishilevich ,  Kristina Yucius ,  Sarah Solomon ,  Mark K. Schlegel ,  Adam Castoreno ,  Charalambos Kaittanis

IPC: C12N15/113 ,  C12N15/66

CPC classification number: C12N15/113 ,  C12N15/66 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2310/321

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the complement component C3 gene (C3). The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria (PNH), lupis nephritis (LN), bullous pemphigoid, pemphigus, e.g., pemphigus vulgaris (PV) and pemphigus foliaceus (PF), and C3 glomerulopathy.